Home » Newsletters » BioWorld Science

BioWorld Science

April 8, 2008

View Archived Issues

Genetic studies find link to lung cancer

Medarex to continue with phase III trial of ipilimumab in advanced melanoma

Phase I clinical study in HIV to use Crucell's recombinant adenovirus serotype 26 vector

Department of Defense awards contract to Cleveland BioLabs to develop Protectan

OxThera completes enrollment in pivotal study of Oxabact in primary hyperoxaluria

Pharmaxis reports positive phase II data for Bronchitol in cystic fibrosis

Abbott launches Zemplar capsules in the U.K.

VIA provides safety update for VIA-2291 ongoing phase II clinical program

In vivo efficacy of BMS-641988, a novel androgen receptor antagonist

Vitreoretinal enrolls patients in phase III Vitreosolve trial for diabetic retinopathy

First preterm infant is enrolled in phase II clinical study of Kiobrina

Clavis initiates recruitment in phase II clinical study of Elacyt in hematological cancers

MMRF awards USD 2.25 million to three universities for proteomics research in myeloma

Biomatrix signs letter of intent with Vibragene to perform genetic testing for biomarkers

Genfit updates sanofi-aventis collaboration programs

Indevus and Orion sign license agreement for Vantas in prostate cancer

Human ApoB-100 related peptide vaccine effects modulated by dose, diet timing

Intravitreal JSM-6427 well tolerated in age-related macular degeneration patients

Hana starts phase I topical menadione trial for EGFR inhibitor-associated rash

Lower strength Kaletra tablet for pediatric use approved in Europe

Improved pharmacokinetics of second-generation FBPase inhibitor for the treatment of diabetes

MediGene reports clinical efficacy data for EndoTAG-1 in pancreatic carcinoma

Vivus enters funding collaboration with Deerfield for erectile dysfunction

New agents for HIV infection reported in recent Osaka University patent

Novel antiglaucoma agents disclosed in recent Allergan patent

New treatment option for Alzheimer's disease imparted in recent Merck & Co. and Sunesis patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...